Biotica - Highly Potent Novel Cyclophilin Inhibitors - Ownership and Business Overview

Life ScienceCompany

Biotica - Highly Potent Novel Cyclophilin Inhibitors Ownership

Who owns Biotica - Highly Potent Novel Cyclophilin Inhibitors?

Biotica - Highly Potent Novel Cyclophilin Inhibitors is owned by Abliva AB. It was acquired on March 11, 2013.

Biotica - Highly Potent Novel Cyclophilin Inhibitors Business Overview

Where is Biotica - Highly Potent Novel Cyclophilin Inhibitors headquartered?

Biotica - Highly Potent Novel Cyclophilin Inhibitors is headquartered in Cambridge, United Kingdom.

What sector is Biotica - Highly Potent Novel Cyclophilin Inhibitors in?

Biotica - Highly Potent Novel Cyclophilin Inhibitors is a life science company.

Life Science M&A Summary in 2013

Out of 60 sectors in the Mergr database, life science ranked 8 in number of deals in 2013. The largest life science acquisition in 2013 was Onyx Pharmaceuticals - which was acquired by Amgen for $10.4B.

Join Mergr to view all 191 acquisitions of life science companies in 2013, including 25 acquisitions by private equity firms, and 166 by strategics.

Biotica Ltd. - Highly Potent, Novel Cyclophilin Inhibitors

Cambridge, CB21 6AD
United Kingdom,

Biotica Ltd. - Highly Potent, Novel Cyclophilin Inhibitors includes novel cyclophilin inhibitors is from a new class of molecules called Sangamides based on a novel and unique chemistry platform of polyketides around which NeuroVive has also acquired the intellectual property rights. These novel cyclophilin inhibitors are expected to form the basis of the next-generation of NeuroVive products for a broad range of diseases including cardio- and neuroprotection.


Company Summary

SECTOR

Life Science

 Subscribe to unlock this and 206,305
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 198K M&A Transactions
  • 202K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 80K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Related Lists for Biotica - Highly Potent Novel Cyclophilin Inhibitors

Life Science Companies , United Kingdom Companies

Related Lists for Life Science Companies

Largest Life Science Companies , Acquisitive Life Science Companies , Recently Acquired Life Science Companies , Recently Sold Life Science Companies , Private Life Science Companies , Public Life Science Companies , Acquired Life Science Companies , PE Backed Life Science Companies

Related Lists for United Kingdom Companies

Largest United Kingdom Companies , Acquisitive United Kingdom Companies , Recently Acquired United Kingdom Companies , Recently Sold United Kingdom Companies , Private United Kingdom Companies , Public United Kingdom Companies , Acquired United Kingdom Companies , PE Backed United Kingdom Companies
Mergr

Product

Company

Legal